Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

Continuing anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

Ace Therapeutics announces its preclinical ophthalmic drug development services to help expedite the discovery of ...

Add Yahoo as a preferred source to see more of our stories on Google. Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial ...